Delivery Order SPE2DB24D3013-SPE2DB25FFPAA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,540.76 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/mL syringes. This competitive delivery order, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, utilizes firm fixed pricing and carries no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a $17,011.92 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Wezlana 90 mg/ml syringes. This firm fixed price contract, with an ultimate completion date of July 25, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside designation...
- The Defense Logistics Agency awarded a delivery order valued at $6,289.42 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/ml syringes. The contract, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $33,849.19 delivery order for Wezlana 90 mg/ml syringes, with an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $11,343.96 to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes, with a completion date of August 8, 2025. This competitive award (no set-aside used) was issued on August 7, 2025, under a firm fixed price contract type. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office operations as a major pharmaceutical distributor supporting...
- The Defense Logistics Agency awarded a $30,488.88 delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes. The contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, utilizes firm fixed price pricing with no set-aside designation. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $13,536.00 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/ml syringes. This firm fixed price, competitively awarded delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among qualified vendors. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes valued at $46,693.54 with an ultimate completion date of August 13, 2025. This firm fixed-price contract, awarded on August 12, 2025, represents a non-competitive set-aside delivery order utilizing the vendor's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $22,924.36 to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a $17,994.08 delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes, with an ultimate completion date of July 29, 2025. This competitive award, issued on July 28, 2025, carries no set-aside designation and is structured as a firm fixed-price delivery order to be performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPAADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,735.28 to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes. This firm fixed-price delivery order, issued on August 5, 2025, represents a non-competitive award executed under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order is executed as a child contract under AmerisourceBergen's $999,999,999.00 Indefinite Delivery/Indefinite Quantity (IDIQ) contract with DLA Troop Support Medical (designated SPE2DX), which extends through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for federal medical procurement, supplying a comprehensive range of medications and medical supplies to support military healthcare systems and the Defense Health Agency. As a major for-profit pharmaceutical distributor headquartered in Pennsylvania, the company has demonstrated capability to fulfill federal medical supply requirements through open competition and maintains an extensive portfolio of pharmaceutical product deliveries across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.7k | 8/5/25 |